Quantbot Technologies LP Increases Stake in Exelixis, Inc. (NASDAQ:EXEL)

Quantbot Technologies LP increased its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 93.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,092 shares of the biotechnology company’s stock after purchasing an additional 5,344 shares during the quarter. Quantbot Technologies LP’s holdings in Exelixis were worth $369,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in EXEL. Magnetar Financial LLC purchased a new position in shares of Exelixis in the fourth quarter worth about $448,000. Teacher Retirement System of Texas increased its stake in Exelixis by 15.6% in the 4th quarter. Teacher Retirement System of Texas now owns 76,017 shares of the biotechnology company’s stock worth $2,531,000 after purchasing an additional 10,264 shares during the period. Harvest Fund Management Co. Ltd bought a new stake in Exelixis in the fourth quarter valued at approximately $440,000. Intech Investment Management LLC boosted its stake in shares of Exelixis by 15.4% during the fourth quarter. Intech Investment Management LLC now owns 267,725 shares of the biotechnology company’s stock valued at $8,915,000 after purchasing an additional 35,684 shares during the period. Finally, Signaturefd LLC boosted its stake in shares of Exelixis by 13.4% during the fourth quarter. Signaturefd LLC now owns 6,959 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 821 shares during the period. 85.27% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Mary C. Beckerle sold 12,210 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares in the company, valued at $1,060,561.28. This represents a 28.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the transaction, the executive vice president now owns 303,310 shares in the company, valued at $11,216,403.80. This trade represents a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 140,343 shares of company stock valued at $5,177,234. Insiders own 2.85% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on EXEL shares. UBS Group upped their price target on shares of Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Guggenheim reaffirmed a “buy” rating and set a $42.00 price objective on shares of Exelixis in a research note on Wednesday, February 12th. Oppenheimer cut Exelixis from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. Brookline Capital Management started coverage on Exelixis in a research report on Monday, December 23rd. They set a “buy” rating for the company. Finally, BMO Capital Markets cut Exelixis from an “outperform” rating to a “market perform” rating and increased their price objective for the stock from $36.00 to $40.00 in a report on Friday, December 20th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Exelixis has an average rating of “Moderate Buy” and a consensus price target of $37.59.

Exelixis Stock Performance

Shares of EXEL stock opened at $36.70 on Friday. Exelixis, Inc. has a one year low of $20.14 and a one year high of $40.02. The company has a market capitalization of $10.27 billion, a price-to-earnings ratio of 20.73, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The company’s 50-day moving average is $35.71 and its 200 day moving average is $33.22.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, research analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.